PBC stands for primary biliary cholangitis, a chronic autoimmune liver disease in which the body’s immune system gradually destroys the small bile ducts inside the liver. Without functioning bile ducts, bile builds up in the liver and damages healthy tissue, eventually leading to scarring (fibrosis) and, if untreated, cirrhosis. PBC was previously called primary biliary cirrhosis, but the name was changed because many patients never progress to cirrhosis, especially with early treatment.
How PBC Damages the Liver
Bile is a digestive fluid your liver produces to help break down fats. It normally flows through a network of tiny ducts out of the liver and into the small intestine. In PBC, immune cells (specifically B cells and T cells) mistakenly attack the cells lining these small bile ducts, destroying them over time. As ducts are lost, bile has nowhere to go. It backs up into the liver, a condition called cholestasis, and begins damaging the surrounding liver cells.
This cycle of inflammation and bile buildup triggers the liver to lay down scar tissue. The disease progresses through four general stages: inflammation limited to the area around the bile ducts, then loss of normal ducts with spreading inflammation, then bands of scar tissue bridging different areas of the liver, and finally full cirrhosis with nodules of regenerating tissue. Progression through these stages takes years or even decades, and many people diagnosed and treated early never reach the later stages.
Who Gets PBC
PBC overwhelmingly affects women. In large cohort studies, the female-to-male ratio is roughly 6 to 1, with women making up about 86% of cases. The average age at diagnosis is around 55, though men tend to be diagnosed a few years later, around 58. The disease is thought to be triggered by environmental factors (infections, toxins, or chemicals) in people who are genetically susceptible. One hallmark of that genetic susceptibility is the presence of a specific antibody called the anti-mitochondrial antibody, or AMA, which is found in the vast majority of PBC patients and is highly specific to the disease.
About one-third of people with PBC also have at least one other autoimmune condition. The most common overlap is with Sjögren’s syndrome, which causes dry eyes and dry mouth. Autoimmune thyroid disease, Raynaud’s phenomenon (cold, painful fingers and toes triggered by temperature changes), scleroderma, and lupus also occur at higher rates than in the general population.
Symptoms to Recognize
Many people with PBC have no symptoms at all when they’re first diagnosed; the disease is often caught through routine blood work showing abnormal liver enzymes. When symptoms do appear, the two most common are fatigue and itching.
Fatigue is reported by up to 80% of PBC patients, and roughly 40% describe it as severe. This isn’t ordinary tiredness. It can be debilitating enough to interfere with work and daily life, and it doesn’t always correlate with how advanced the liver disease is. Itching (pruritus) affects between 20% and 70% of patients and is a major driver of reduced quality of life. It can be widespread, often worse at night, and is caused by bile salts accumulating under the skin rather than flowing through the digestive tract normally.
As the disease advances, other signs can develop: dry eyes and mouth, darkened skin patches, small fatty deposits under the skin (especially around the eyes), bone thinning, and in later stages, jaundice (yellowing of the skin and eyes).
How PBC Is Diagnosed
Diagnosis typically requires two of three criteria. The first is a blood test showing elevated alkaline phosphatase (ALP), a liver enzyme that rises when bile flow is blocked. The second is a positive AMA blood test. About 5% to 10% of PBC patients are AMA-negative, in which case other specific antibodies can confirm the diagnosis. The third criterion is a liver biopsy showing the characteristic pattern of bile duct destruction and inflammation. Most people are diagnosed with blood tests alone and never need a biopsy.
Because the disease is often found incidentally through elevated liver enzymes, many patients are diagnosed before symptoms begin. This is actually good news: earlier detection means earlier treatment and a better long-term outlook.
Treatment Options
The standard first-line treatment for all PBC patients is ursodeoxycholic acid, commonly called UDCA or by the brand name Ursodiol. It’s a synthetic version of a naturally occurring bile acid that helps move bile through the liver, reduces inflammation, and slows disease progression. All major hepatology guidelines recommend a lifelong daily dose based on body weight. Multiple clinical trials have shown that UDCA significantly improves liver function markers, delays disease progression, and reduces the need for liver transplantation.
Not everyone responds adequately to UDCA, though. For those patients, a newer class of medications has recently become available. Seladelpar received FDA approval as a second-line treatment for PBC. It works by activating a receptor involved in bile acid regulation and fat metabolism, and early clinical data suggests it can improve liver enzyme levels in patients who didn’t respond to UDCA alone. It may also help with itching, which UDCA does not reliably control.
For patients whose PBC progresses to end-stage liver disease despite treatment, liver transplantation remains an option. PBC can recur in a transplanted liver, but outcomes after transplant are generally favorable.
What to Expect Long Term
The outlook for PBC has improved dramatically with modern treatment. Patients who are diagnosed early and respond well to UDCA can expect a normal life expectancy. The key is adequate treatment response: those who respond to UDCA have significantly higher transplant-free survival than those who don’t. This is why regular monitoring of liver enzymes after starting treatment matters. If your numbers aren’t improving sufficiently, your doctor can add or switch therapies rather than waiting for the disease to progress.
Diet and Lifestyle With PBC
There’s no single “PBC diet,” but dietary choices can meaningfully support liver health alongside medication. A Mediterranean-style eating pattern, rich in fruits, vegetables, whole grains, and healthy fats, is often recommended because of its anti-inflammatory properties. Aiming for five or more servings of fruits and vegetables daily helps ensure you’re getting enough vitamins and antioxidants, which is especially important because bile flow problems can impair the absorption of fat-soluble vitamins (A, D, E, and K).
Fiber-rich foods like oatmeal, brown rice, and whole-grain bread can improve liver function and protect against fatty liver disease developing on top of PBC. Foods high in omega-3 fatty acids, such as salmon, walnuts, and flaxseed, are easier for the liver to process than saturated fats and also help combat inflammation. On the other hand, heavily marbled red meat, processed meats like bacon and sausage, full-fat dairy, and foods high in added sugar are worth limiting. Excess sugar can lead to fat buildup in the liver, compounding the damage from PBC itself.
Coffee appears to have a protective effect on the liver. Research suggests that caffeine may activate a receptor inside the liver that can slow PBC progression, though the exact mechanism isn’t fully understood. Alcohol, by contrast, is a direct liver stressor and should be minimized or avoided entirely. As PBC advances, a low-sodium diet becomes particularly important to help prevent fluid retention, a common complication of advanced liver disease.